We support the FLCCC treatment protocols and the wide range of medications included in each.
AMA Regenerative Medicine & Skincare is honored to be affiliated with the Front Line Covid-19 Critical Care Alliance (FLCCC) in providing advanced medical protocols for…
- The prevention of COVID-19.
- Effective “At Home” treatment of patients who have contracted the SARS-CoV-2 virus.
- For people suffering from COVID-19 Long-Haul Syndrome.
If you are interested in learning about these protocols, please use the form below or call (949) 208-9066. We are pleased to help you!
Request a COVID-19 TeleMedicine Appointment
NOTE: There is a fee for a TeleMedicine appointment with our medical staff which includes prescribing the necessary medications.
Our Experience with COVID
Our first patient was Dr. Milgrom in December 2019.
By the end of Delta and the emergence of Omicron we had treated approximately 2500 patients with a 100% success rate. The vast majority of these patients recovered at home using the FLCCC Early Treatment Protocol.
Those who were already beyond the second week of their illness and experiencing more serious symptoms were treated in our clinic with the 5 Integrative Modalities that we were having remarkable success with.
We lost only 2 patients who had already been swallowed up by the machine and admitted for ICU care before their families notified us of their condition. The hospital refused to allow us to treat them. They both died… alone in isolation… while on ventilators.
The credit for this extraordinary success in the early months of the pandemic belongs to Dr. Zelenko (may his memory be a blessing), and thereafter to the FLCCC who became our major source of ongoing guidance.
And of course to God.
About the FLCCC
The FLCCC was formed by doctors specializing in critical care in March 2020, at the beginning of the Coronavirus pandemic, the “Front Line COVID-19 Critical Care Alliance” is now a 501(c)(3) non-profit organization dedicated to developing highly effective treatment protocols to prevent the transmission of COVID-19 and to improve the outcomes for patients ill with the disease.
The FLCCC is dedicated to
- Reviewing all emerging published medical literature on COVID-19 from in-vitro, animal, clinical, and epidemiological studies.
- Developing effective treatment protocols for COVID-19 that evolve by incorporating newly identified, applicable therapeutic and pathophysiologic insights.
- Educating physicians on safe and effective treatment approaches to all phases of COVID-19, from disease prevention strategies to the use of our combination-based therapy protocols in both early-stage (I-MASK+) and hospitalized patients (MATH+).
- Improving outcomes for people impacted by COVID-19 disorders through preventive and treatment strategies designed to optimize health.
- Teaching the public ways to prevent transmission of the virus and to advocate for the best possible care.
- Coordinating and accelerating the formation of research studies that will support effective prevention and therapeutic treatments for all impacted by COVID-19.
We accomplish these goals by sponsoring high quality medical education for both the public and health care providers, via the publication of scientific manuscripts, media interviews, and medical lectures for medical providers and the public.
Disclaimer: though everything represented on our website regarding the science of early treatment comes directly from reputable publications, books and scientific journals; and though hundreds of these articles are available on official government websites (https://www.ncbi.nlm.nih.gov/pubmed/), and even though these medications are on the World Health Organization’s Model List of Essential Medicines, they have not been evaluated by the US Food and Drug Administration. The US Food and Drug Administration has not approved these medications as a treatment for Covid-19 and such use is considered “off-label.”